Breaking
European Research Revolution: Day 1 HighlightsRAPS Euro Convergence: Key Regulatory Updates - Day 1Cellenkos Receives FDA Clearance for CK0802 Phase 2a Trial in Steroid-Refractory GVHD
🇪🇺 EMA

Pediatric Diseases

Page 1 • 1 item

Gain critical insights into global pediatric disease drug development, clinical trials, regulatory pathways, and investment opportunities.

Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations
NewsPediatric OncologyApr 23, 2026

Ipsen Receives EU Approval for Ojemda (Tovorafenib) to Treat Pediatric Brain Cancer with BRAF Mutations

Ipsen secures conditional EU marketing authorization for Ojemda (tovorafenib) to treat pediatric low-grade glioma with BRAF alterations in patients 6 months and older.

Sofia Alvarez